Paramit Chowdhury

The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment

Éric Rondeau, Marie Scully, Gema Ariceta et al. · Kidney International · 2020 · 219 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 215 citations · Full text

Medicine, Internal Medicine, Nephrology +12

Pivotal role of CD4+ T cells in renal fibrosis following ureteric obstruction

Thomas T. Tapmeier, Amy Fearn, Kathryn Brown et al. · Kidney International · 2010 · 145 citations · Full text

Medicine, Immunology, Nephrology +17

Toll-like receptors TLR2 and TLR4 initiate the innate immune response of the renal tubular epithelium to bacterial products

Paramit Chowdhury, Steven H. Sacks, Neil Sheerin · Clinical & Experimental Immunology · 2006 · 91 citations · Full text

Life Sciences, Immunology, Microbiology +17

Nontransgenic Hyperexpression of a Complement Regulator in Donor Kidney Modulates Transplant Ischemia/Reperfusion Damage, Acute Rejection, and Chronic Nephropathy

Julian R. Pratt, Miriam E. Jones, Jun Dong et al. · American Journal Of Pathology · 2003 · 89 citations · Full text

Medicine, Immunology, Nephrology +17